Literature DB >> 19434460

Early assessment of therapeutic response using FDG PET in small cell lung cancer.

Y Yamamoto1, R Kameyama, M Murota, S Bandoh, T Ishii, Y Nishiyama.   

Abstract

PURPOSE: We evaluated the ability of 2-deoxy-2-(18)F-fluoro-D-glucose (FDG) positron emission tomography (PET) in the early assessment of therapeutic response in patients with small cell lung cancer (SCLC). PROCEDURES: FDG PET studies were performed before (baseline PET), after the first cycle of chemotherapy (early PET), and after completion of therapy (final PET) in 12 patients with SCLC. The standardized uptake value (SUVmax) was measured. Metabolic response was defined as a reduction in SUVmax of more than 20% on the early PET, compared with the baseline PET. Tumor response after completion of therapy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST).
RESULTS: Eleven patients were classified as metabolic responders and had a mean (+/-SD) reduction in SUVmax of 57.9 +/- 10.3%. The remaining one patient was classified as a metabolic nonresponder with a reduction in SUVmax of 13.5%. In all patients, metabolic response after the first cycle of chemotherapy was associated with subsequent response according to RECIST.
CONCLUSIONS: FDG PET has the potential to identify the therapeutic response in patients with SCLC as early as after the first cycle of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434460     DOI: 10.1007/s11307-009-0227-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  24 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.

Authors:  Yeh-You Shen; Yu-Chien Shiau; Jhi-Joung Wang; Shung-Tai Ho; Chia-Hung Kao
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

Review 3.  The mechanism of accumulation of tumour-localising radiopharmaceuticals.

Authors:  E K Pauwels; V R McCready; J H Stoot; D F van Deurzen
Journal:  Eur J Nucl Med       Date:  1998-03

4.  Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

Authors:  V W Rusch; D J Giroux; M J Kraut; J Crowley; M Hazuka; D Johnson; M Goldberg; F Detterbeck; F Shepherd; R Burkes; T Winton; C Deschamps; R Livingston; D Gandara
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

Review 5.  Management of small cell lung cancer: current state of the art.

Authors:  D H Johnson
Journal:  Chest       Date:  1999-12       Impact factor: 9.410

6.  Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.

Authors:  Hinrich A Wieder; Ambros J Beer; Florian Lordick; Katja Ott; Michael Fischer; Ernst J Rummeny; Sibylle Ziegler; Jörg R Siewer; Markus Schwaiger; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

7.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

8.  FDG-PET evaluation of therapeutic effects on VX2 liver tumor.

Authors:  N Oya; Y Nagata; N Tamaki; T Takagi; R Murata; Y Magata; M Abe; J Konishi
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

9.  Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.

Authors:  Robert Chin; Trent W McCain; Antonius A Miller; Donnie P Dunagan; Jose Acostamadiedo; L Douglas Case; Beth A Harkness; Lee P Adler; Edward F Haponik
Journal:  Lung Cancer       Date:  2002-07       Impact factor: 5.705

10.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

Authors:  S S Gambhir; C K Hoh; M E Phelps; I Madar; J Maddahi
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

View more
  14 in total

Review 1.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

2.  Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.

Authors:  Judith van Loon; Claudia Offermann; Michel Ollers; Wouter van Elmpt; Erik Vegt; Ali Rahmy; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2011-05-14       Impact factor: 6.280

Review 3.  [PET/CT for diagnostics and therapy stratification of lung cancer].

Authors:  C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

4.  Optical glucose analogs of aminolevulinic acid for fluorescence-guided tumor resection and photodynamic therapy.

Authors:  Eduardo H Moriyama; Weiguo Cao; Tracy W Liu; Han Lin Wang; Peter D Kim; Juan Chen; Gang Zheng; Brian C Wilson
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

Review 5.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

6.  A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Authors:  Paul Flechsig; Clemens Kratochwil; Arne Warth; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

Review 7.  Positron emission tomography-computed tomography in the management of lung cancer: An update.

Authors:  Punit Sharma; Harmandeep Singh; Sandip Basu; Rakesh Kumar
Journal:  South Asian J Cancer       Date:  2013-07

8.  Prognostic Value of Pre- and Post-Treatment FDG PET/CT Parameters in Small Cell Lung Cancer Patients.

Authors:  Hyoungwoo Kim; Ie Ryung Yoo; Sun Ha Boo; Hye Lim Park; Joo Hyun O; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2017-08-11

9.  18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study.

Authors:  Tine Nøhr Christensen; Seppo W Langer; Katrine Engholm Villumsen; Helle Hjorth Johannesen; Johan Löfgren; Sune Høgild Keller; Adam Espe Hansen; Andreas Kjaer; Barbara Malene Fischer
Journal:  Eur J Hybrid Imaging       Date:  2020-01-27

10.  Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

Authors:  D Ziai; T Wagner; A El Badaoui; A Hitzel; J B Woillard; B Melloni; J Monteil
Journal:  Cancer Imaging       Date:  2013-03-05       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.